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Abstract
Background: Bone marrow-derived mesenchymal stem cells (MSC) improve myocardial recovery after ischemia/reperfusion
(I/R) injury. These effects are mediated in part by the paracrine secretion of angiogenic and tissue growth-promoting factors.
Toll-like receptor 4 (TLR4) is expressed by MSC and induces apoptosis and inhibits proliferation in neuronal progenitors as
well as many other cell types. It is unknown whether knock-out (KO) of TLR4 will change the paracrine properties of MSC
and in turn improve MSC-associated myocardial protection.
Methodology/Principal Findings: This study explored the effect of MSC TLR4 on the secretion of angiogenic factors and
chemokines in vitro by using ELISA and cytokine array assays and investigated the role of TLR4 on MSC-mediated myocardial
recovery after I/R injury in an isolated rat heart model. We observed that MSC isolated from TLR4 KO mice exhibited a
greater degree of cardioprotection in a rat model of myocardial I/R injury. This enhanced protection was associated with
increased angiogenic factor production, proliferation and differentiation. TLR4-dificiency was also associated with decreased
phosphorylation of PI-3K and AKT, but increased activation of STAT3. siRNA targeting of STAT3 resulted in attenuation of
the enhanced cardioprotection of TLR4-deficient MSC.
Conclusions/Significance: This study indicates that TLR4 exerts deleterious effects on MSC-derived cardioprotection
following I/R by a STAT3 inhibitory mechanism.
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Introduction
Accumulating evidence indicates that MSC mediate their
beneficial effects at least in part through the production of
cytoprotective paracrine factors that reduce inflammation, de-
crease apoptosis and improve myocardial function [1,2,3,4,5,
6,7,8,9]. These paracrine factors also play a pivotal role in MSC-
mediated chemotaxis and angiogenesis [10,11,12,13,14]. Vascular
endothelial growth factor (VEGF), hepatocyte growth factor
(HGF) and insulin-like growth factor-1 (IGF-1) all have been
implicated in MSC-mediated functional recovery of the heart after
ischemic injury [5,15,16,17]. However, in spite of these encour-
aging experimental results, clinical trials have demonstrated that
these stem cells have a modest and short-lived benefit in restoring
cardiac function following ischemia [18,19,20,21,22]. Therefore,
there is a critical need to discern the mechanisms by which MSC
mediate their experimental benefits, and the ways in which their
function can be optimized for potential clinical benefit.
The inflammatory environment of the injured heart likely
restricts the therapeutic benefit of the implanted MSC. Thus,
genetic modification of stem cells may represent an important
strategy in improving stem cell therapy. Toll like receptors 4
(TLR4) are expressed by MSC and may play an deleterious role in
MSC-mediated protection [23]. TLR4 is known to induce
apoptosis and inhibit proliferation in neuronal progenitors as well
as many other cell types [24,25]. Conversely, the deficiency of
TLR4 or its downstream effectors results in decreased proin-
flammatory cytokine production and increased differentiation and
proliferation [23,25]. Although it is well established that MSC
exert a protective role in hearts following acute ischemia and
reperfusion (I/R) injury [3,5,15,17,26], it is unknown whether
knock-out of TLR4 will increase MSC-mediated cardioprotection.
Furthermore, it is unclear if TLR4 regulates the paracrine
properties of MSC. Finally, it is not known whether TLR4
regulates the activation of intracellular kinases such as STAT3,
MAPK, PI-3K and AKT, whose activity has been shown to
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[16,27,28]. We therefore hypothesized that TLR4-knockout
(TLR4KO) MSC would confer a greater degree of cardioprotec-
tion against acute I/R by increasing angiogenic and tissue growth-
promoting factor secretion, and that the protective effects of
TLR4KO MSC would be associated with differential activation of
the PI-3K, AKT, MAPK or STAT3 signaling pathways.
Results
MSC isolated from WT or TLR4KO mice express Sca-1,
CD44 and are capable of differentiating into adipocytes
and osteocytes
In order to demonstrate that the cells used in this study were
indeed MSC, we determined whether the cells isolated from the
mouse bone marrow expressed MSC surface markers and whether
they could be induced to differentiate. Based on our flow
cytometry data, the cells were negative for CD45, CD11b,
CD106, CD117, CD90 and positive for stem cell antigen-1 (Sca-1)
and the mesenchymal stem cell marker CD44 (Fig. 1A).
Interestingly, a small population of MSC in both genotypes was
positive for CD34 (Fig. 1A). To assess their ability to differentiate
into mesodermal lineages, MSC were cultured with media
containing adipogenic or osteogenic supplements. As shown in
Fig. 1B, MSC of both genotypes cultured without differentiation
media (uninduced) did not express fatty acid binding protein 4
(FABP-4, a marker specific to adipocytes) or osteopontin (specific
to osteocytes). In contrast, cells grown in media supplemented with
adipogenic or osteogenic induction agents did express FABP-4 or
osteopontin. Compared with wildtype (WT) MSC, more
TLR4KO MSC had differentiated into adipocytes and osteocytes
when assessed under the microscope (Fig. 1B). Thus these isolated
stromal cells possessed the phenotypic cell surface markers of MSC
and were able to differentiate into adipocytes and osteoblasts,
indicating that these cells are MSC.
TLR4KO MSC have a higher rate of proliferation than WT
MSC
To investigate whether TLR4KO MSC exhibited altered rate of
proliferation, the proliferation rates of both genotypes were
examined by 1) BrdU incorporation and 2) direct cell counting.
We observed that TLR4KO MSC incorporated two-fold more
BrdU as compared to WT MSC (Figure 2A). Corroborating this
result,thenumbersofTLR4KOMSCwereatleasttwo-foldgreater
when compared with WT MSC cultured under similar condition,
indicating increased proliferation in the TLR4KO cells (Figure 2B).
The production of VEGF, HGF and IGF-1 in WT and
TLR4KO MSC
0.5610
5 cells?well
21?ml
21 from WT or TLR4KO MSC were
plated and the supernatants collected after 24 h incubation and
Figure 1. MSC express Sca-1 and CD44 and are capable of differentiating into adipocytes and osteocytes. A: WT andTLR4KO MSC were
incubatedwithspecificsurfacemarkerantibodiesorisotypecontrolantibodiesandsubjectedtoflowcytometryanalysis.B:MSCinbothgenotypeswere
cultured with induction media for 3–4 weeks to induce cell differentiation. The expression of FABP-4 (adipocyte-marker) or osteopontin (osteocyte-
marker) was examined using a florescence microscopy (NL557-positive red staining). Representative fields are shown at 1006magnification.
doi:10.1371/journal.pone.0014206.g001
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MSC produced significantly more total VEGF compared to WT
MSC over a 24 h period (Fig. 3A). TLR4KO MSC also produced
significantly more total HGF (Fig. 3B). In contrast, IGF-1
production was significantly lower in TLR4KO MSC (Fig. 3C).
Immediately after supernatant collection, the cells were trypsinized
and counted. The number of cells per well was (0.8460.05) 610
5
and (1.560.11) 610
5 for WT and TLR4KO MSC, respectively
(n=3).
The differential chemokine expression in WT and TLR4KO
MSC
To study the role of TLR4 in the chemokine production in
MSC, the amount of chemokines in the cell supernatant was
measured. 0.5610
5 cells?well
21?ml
21 from WT or TLR4KO
MSC were plated and the supernatants collected after 24 h
incubation. As shown in Fig. 4A, MSC of both genotypes were a
potent source of a variety of chemokines namely TIMP
metallopeptidase inhibitor 1 (TIMP-1), chemokine (C-X-C motif)
ligand 1 (CXCL1/KC), macrophage colony-stimulating factor (M-
CSF), mouse monocyte chemoattractant protein-1 (MCP-1/JE),
the chemokine CC chemokine ligand (CCL) 5/RANTES and
stromal derived factor-1 (SDF-1). The production of TIMP-1, KC,
M-CSF and JE was significantly higher in TLR4KO MSC;
whereas the production of RANTES and SDF-1 was lower
(Fig. 4B). Immediately after supernatant collection, the cells were
trypsinized and counted. The number of cells per well was
(0.8660.06) 610
5 and (1.960.2) 610
5 for WT and TLR4KO
MSC, respectively (n=4).
The activation of intracellular kinases in both genotypes
We reported previously that the activity of intracellular kinases,
such as PI-3K-AKT, MAPK and STAT3 modulate the paracrine
properties of MSC [16,27,28]. Therefore, in this study, the activity
of these signaling molecules was examined in both genotypes. As
shown in Fig. 5A, the phosphorylated STAT3 was significantly
Figure 2. TLR4KO MSC have a higher rate of proliferation than WT MSC. A: WT and TLR4KO MSC were plated in 96-well plate (5000 cells per
well) for 24 h and then incubated with BrdU (10 mM) for an additional 24 h. BrdU incorporation was quantified after incubation. N=5–6/group. B: WT
and TLR4KO MSC were plated in 12-well plates (0.5610
5 cell/well). After 24 h, cells were trypsinized and counted using an automatic cell counter.
Data are the combination of five independent experiments. Results are mean 6 SEM, * p,0.05 vs. WT control.
doi:10.1371/journal.pone.0014206.g002
Figure 3. TLR4KO MSC produced higher levels of VEGF and HGF but lower levels of IGF-1 compared with WT MSC. WT and TLR4KO
MSC were plated in 12-well plates (0.5610
5 cell/well). After 24 h, supernatant was collected and the total amounts of VEGF (A), HGF (B) and IGF-1(C)
were measured. Data are representative of at least three independent experiments. Results are mean 6 SEM; n=3/group. * p,0.05 vs. WT control.
doi:10.1371/journal.pone.0014206.g003
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decreased activation of the PI-3K-AKT signaling pathway
(Fig. 5B–C). TLR4 deficiency did not change ERK activation
(Fig. 5D).
Knockout of TLR4 improves MSC-mediated
cardioprotection following ischemic injury
In order to examine whether TLR4 deficiency improved MSC-
mediated cardioprotection in an isolated rat heart I/R model, 1
million MSC of either genotype was infused into the coronary
system before ischemic injury. The indexes of left ventricular
performance, namely, left ventricular developed pressure (LVDP),
end diastolic pressure (EDP, indicating the compliance of
ventricular muscle), maximum +dP/dt (rate of pressure rise during
ventricular contraction) and 2dP/dt (rate of pressure fall during
ventricular relaxation) were monitored constantly. Figure 6A is the
representative recording trace of developed pressure of isolated rat
hearts of different groups. Treatment of hearts with MSC of either
genotype prior to ischemia resulted in significantly improved post-
ischemic functional recovery as compared to vehicle controls. This
was demonstrated, specifically, via improved LVDP, +dp/dt and
2dp/dt in the experimental groups as compared to the vehicle
controls (Figure 6B–I). Compared to WT MSC, TLR4KO MSC
conferred a greater degree of myocardial protection following I/R.
The hearts infused with TLR4KO MSC had higher LVDP
compared with those infused with WT MSC after I/R (Figure 6A–
F). However, the EDP was not different among all tested groups
(Figure 6G–H). The similar value of EDP of hearts in different
groups may suggest the equivalence of injury after I/R.
siRNA specifically targeting STAT3 decreased STAT3
expression in TLR4 KO MSC
To investigate the role of STAT3 in the paracrine signaling and
the cardioprotection of TLR4KO MSC following ischemia and
reperfusion injury, STAT3 siRNA was used to suppress the
expression of STAT3. Three days after transfection, the expression
of STAT3 (86 KD) was decreased in groups treated with STAT3
siRNA compared to the cells transfected with GAPDH siRNA
(Fig. 7A). siRNA targeting of STAT3 suppressed the activation of
PI-3K and ERK, but increased the phosphorylation of AKT
(Fig. 7B–D).
siRNA targeting of STAT3 decreased the production of
growth factors in TLR4KO MSC
siRNA targetingof STAT3 in TLR4KO MSC decreased the
production of VEGF, HGF and IGF-1. As shown in Fig. 8A–C,
the release of VEGF, HGF and IGF-1 from TLR4 KO MSC
transfected with STAT3 siRNA was significantly lower compared
with these transfected with GAPDH siRNA. However, siRNA
targeting of STAT3 did not suppress the proliferation of
TLR4KO cells (Figure 8D).
Knock-down of STAT3 altered the chemokine expression
profile in TLR4KO MSC
To investigate the role of STAT3 in the cytokine production in
TLR4KO MSC, the levels of cytokines in the cell supernatants
were measured. siRNA targeting of STAT3 decreased TIMP-1
expression but increased the expression of KC, RANTES and
Chemokine (C-X-C motif) ligand 10 (CXCL10/IP-10) (Fig. 9).
Figure 4. WT and TLR4KO MSC secrete various chemokines. WT and TLR4KO MSC were plated in 12-well plates (0.5610
5 cell/well). After 24 h,
supernatants were collected for cytokine array assay. A: representative cytokine array blots are shown. B: Array signals from images of scanned X-ray
films were analyzed and quantified as pixel densities. Data are the combination of two independent experiments. Results are mean 6 SEM, n=4/
group, * p,0.05 vs. WT control.
doi:10.1371/journal.pone.0014206.g004
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cardioprotection associated withTLR4KO MSC treatment
Transfection of STAT3 siRNA significantly decreased the
myocardial protection associated with TLR4KO MSC. Figure 10A
shows the representative recording trace. The hearts infused with
STAT3 ablated TLR4KO MSC exhibited less post-ischemic
functional recovery as compared those infused with GAPDH ablated
TLR4KO MSC. This decreased functional recovery was evidenced
by decreased LVDP, +dp/dt and 2dp/dt in the STAT3 siRNA
groups as compared to the GAPDH groups (figure 10B–G). The EDP
was not different between the tested groups (Figure 10H–I).
Discussion
Delineating the factors and mechanisms that regulate the paracrine
properties, proliferation, and differentiation of MSC is crucial as it may
allow us to optimize MSC function prior to therapeutic use. While
TLR4 has received much attention for its deleterious roles in I/R
injury of heart and multiple other organs, such as liver [29], lung [30],
kidney [31], and brain [32], accumulating evidence indicates that
TLR4 may suppress the proliferation, survival, cytokine production,
differentiation and immunomodulatory activity of MSC and other
progenitors. For example, the deficiency of TLR4 or its downstream
effectors decreases MSC proinflammatory cytokine production,
increases survival, differentiation and proliferation of murine MSC
[23,25,33]. Interestingly, murine MSC may exert their immunomod-
ulatory effect by contact with the surrounding T-cells, whereas human
MSC suppress the proliferation of host T-cells by releasing soluble
factors, such as Jagged-1, transforming growth factor b and HGF
[10,34,35]. It remains to be elucidated whether the deficiency of TLR4
improves the survival of implanted MSC in target tissue by escaping
host immune system.
Figure 5. Intracellular kinase activation in WT and TLR4KO MSC. WT and TLR4KO MSC were plated in 12-well plates (0.05610
6 cell/well).
After 24 h, cell lysates were collected and the activation of of STAT3 (A), PI-3K (B), AKT (C) and ERK (D) were measured by Western blot. The upper
panels in each subfigure show the representative Western blots. The lower panels of each subfigure represent the quantified signal ratio of the
activated form to total form (or actin loading control) from the Western blot. The data represent three independent experiments. Results are mean 6
SEM, n=3–4 group, * p,0.05 vs. WT control. Representative blot out of 4 independent experiments are shown.
doi:10.1371/journal.pone.0014206.g005
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14206Figure 6. Intracoronary infusion of TLR4KO MSC provided greater cardioprotection compared to WT MSC. One million WT or TLR4KO
MSC were infused into the coronary circulation prior to global ischemia. The left ventricular function in vehicle (grey, n=8 rat hearts), WT MSC (white,
n=6), and TLR4KO MSC treated hearts (black, n=6) is presented. A: representative recording trace from the hearts infused with vehicle, MWT or
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greater capability to differentiate, proliferate and produce more
angiogenic factors such as VEGF, HGF, chemokine KC and JE
compared to their WT counterparts. These observations about
TLR4KO MSC were associated with improved myocardial
recovery in MSC treated heart in an isolated heart model of
acute global I/R.
It is unlikely that the improved myocardial recovery observed in
our study resulted from the expression of cell surface markers as
both WT and TLR4KO MSC displayed similar phenotypic
expression. Interestingly, a population of WT MSC demonstrated
positive CD34 staining. CD34 has been widely used as a surrogate
marker for hematopoietic stem cells, however, the CD34-positive
cells in our preparation are unlikely to be contaminated
hematopoietic stem cells due to the lack of other hematopoietic
stem cell markers such as CD45 and CD11b. In addition, CD34
has been reported to be expressed on both human and murine
mesenchymal stem cells [36,37,38]. These CD34-positive MSC
Figure 7. The role of STAT3 siRNA on the activation of STAT3, PI-3K-AKT and MAPK pathway. TLR4KO MSC were plated in 12-well plates
at 0.5610
5cells?well
21?ml
2124 h prior to siRNA transfection. The lipofectamine-siRNA complex (100 nM) was added on culture day 2. Medium was
then changed after 2 days (day 4 in culture) of transfection. 3 days after transfection (day 5 in culture), cell extracts were prepared for performing
Western blots. The activity of STAT3, PI-3K, AKT and ERK was examined by using Western blot. The upper panels in each subfigure show the
representative Western blots. The lower panels of each subfigure demonstrate the quantified signals from images of the Western blot. A: STAT3
specific siRNA, but not GAPDH siRNA decreased phosphorylated (P) STAT3 and total (T) STAT3. B–D: STAT3 siRNA suppressed the activation of PI-3K
and ERK, but increased the activation of AKT. N=3 (representative blot out of 6 independent experiments are shown).
doi:10.1371/journal.pone.0014206.g007
TLR4KO MSC. The line-graphs represent left ventricular function parameters over time including LVDP (% of equilibrium, B), + dP/dt (% of equilibrium,
D), 2 dP/dt (% of equilibrium, F) and EDP (H). Recovery at end reperfusion is indicated in bar graph form: LVDP (C), + dP/dt (E), 2dP/dt (G) and EDP (I).
All results are reported as the mean 6 SEM. * p,0.05 vs. Vehicle; # p,0.05 vs. WT MSC group.
doi:10.1371/journal.pone.0014206.g006
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including fibroblast growth factor 7 and hepatoma-derived growth
factors [36]. Whether these CD34-positive cells used in our study
can lead to neovascularization in ischemic heart remains unknown
and may warrant further investigation in a chronic infarction
model.
Despite the common cell surface markers between WT and
TLR4KO MSC, TLR4KO MSC proliferated more rapidly and
could be induced to differentiate to a greater degree. These results
are consistent with previous reports that the deficiency of TLR4 or
its downstream adaptors, MyD88 and TICAM1 resulted in
enhanced proliferation and neuronal differentiation in adult
neural and retinal progenitor cells in vivo [25,33]. The increased
rate of proliferation may result from increased basal production of
VEGF [39], HGF [40], TIMP-1 [41], KC [42], M-CSF [43], and
JE [44] whose activity have been demonstrated to increase the
proliferation of progenitor cells and many other cell types.
Interestingly, VEGF [45], HGF [46], TIMP-1 [47], KC [48],
M-CSF, [49] and JE [50] are also potent inducers of cell
differentiation. These previously reported results together with our
observations suggest that TLR4KO MSC may have an increased
ability to proliferate and differentiate into end-organ cells via
VEGF, HGF, TIMP-1, KC, M-CSF, and JE-dependent mecha-
nisms. However, some caution must be taken as Rolls et al
observed that TLR4 deficient cells after differentiation had
decreased rates of survival, suggesting that other factors control
the long-term fate of these differentiated cells [25]. Therefore, it is
important to identify the factors that promote the survival of the
differentiated MSC. Moreover, in order to optimize MSC-
mediated protection, it is essential to regulate the balance between
proliferation and differentiation. Excessive proliferation may lead
to tumor formation whereas overly rapid differentiation may
deplete the population of implanted stem cells. While our model of
acute I/R answers the important question of how MSC function in
the setting of global I/R as encountered during cardiac surgery or
heart transplantation, however, it is not suited for studying the
survival and differentiation of TLR4KO MSC implanted in
ischemic heart tissue. A chronic infarct model such as the left
anterior coronary artery ligation model is planned in the future
investigations.
It is well established that MSC are capable of producing large
quantities of cytoprotective growth factors and angiogenic
chemokines that reduce inflammation, apoptosis, promote angio-
genesis and improve end organ function [1,2,3,4,5]. However, the
host inflammatory response and other endogenous molecules
released in response to tissue injury may decrease MSC-mediated
protection. Therefore, genetically modified MSC with increased
production of angiogenic growth factors and anti-inflammatory
cytokines as well as decreased production of pro-inflammatory
cytokines may be a better choice for cell-based therapy. In this
study, we observed that the basal production of angiogenic factors
such as VEGF [51], HGF [52], KC [53], and JE [54] was
Figure 8. TLR4KO MSC ablated with STAT3 produced lower levels of VEGF, HGF and IGF-1 compared with TLR4KO MSC ablated
with GAPDH. TLR4KO MSC were plated in 12-well plates at 0.5610
5cells?well
21?ml
2124 h prior to siRNA transfection. The lipofectamine-siRNA
complex (100 nM) was then added on culture day 2. Medium was then changed after 2 days (day 4 in culture) of transfection. 3 days after transfection
(day 5 in culture), the supernatant was collected from TLR4KO MSC either transfected with STAT3 siRNA or GAPDH siRNA and was analyzed by using
VEGF, HGF and IGF-1 ELISA. Total amounts of VEGF (A), HGF (B) and IGF-1(C) were examined. siRNA targeting of STAT3 did not change the
proliferation of TLR4KO cells (D). Data are representative of at least three independent experiments. Results are mean 6 SEM; n=3/group. * p,0.05
vs. GAPDH ablated group.
doi:10.1371/journal.pone.0014206.g008
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these factors can facilitate angiogenesis and promote tissue repair
and wound healing. Additionally, TLR4KO MSC produced less
of the inflammatory chemokine RANTES. The differential
cytokine/chemokine expression profile of TLR4KO MSC may
result from decreased activity of PI-3K, AKT and increased
STAT3 when compared to the WT MSC. The activity of these
kinases regulates the release of paracrine factors from MSC
[16,55,56]. Our in vitro observations therefore suggest that
TLR4KO MSC may be a better choice for cell therapy of
ischemic heart disease as a result of increased production of
angiogenic factors and decreased production of proinflammatory
cytokines/chemokines. However, some caution must be taken as
MSC derived from TLR4KO mice may carry distinct phenotypes
unrelated to the function of TLR4. Moreover, we cannot rule out
the possibility that a distinct cell population may have been
selected as using MSC isolated from different animals. Therefore,
the experiments using MSC overexpressed TLR4 or using TLR4
specific siRNA are necessary to elucidate the role of TLR4 in
MSC-mediated cardioprotection in future investigations.
In this study pre-ischemic intracoronary infusion of TLR4KO
MSC improved post-ischemic heart function as evidenced by
increased LVDP, +dp/dt and 2dp/dt compared to WT MSC and
the vehicle treatment groups. Since these protective effects occur
less than 1 hour after injury, it is unlikely that the cardioprotective
benefit is due to any meaningful amount of donor MSC
differentiation and regeneration. The acute MSC-mediated
protection in this study is more likely the result of paracrine
factors released from these cells. These factors may exert their
cytoprotective effects by binding to their respective receptors on
cardiomyocytes and/or other surrounding cells.
The mechanism for the increased levels of paracrine factors
appears to involve STAT3. At baseline, STAT3 levels were
significantly higher in the TLR4KO MSC. siRNA targeting of
STAT3 in TLR4KO MSC decreased the expression of VEGF,
HGF, IGF-1 and TIMP-1, but increased levels of KC, IP-10 and
the proinflammatory chemokine RANTES. In addition, siRNA
targeting of STAT3 abolished the difference in functional recovery
associated with TLR4KO MSC treatment, suggesting that
TLR4KO MSC exert their cardioprotection by STAT3-depen-
dent mechanisms. Overexpression of STAT3 in MSC may present
a novel strategy to optimize their therapeutic potential.
Materials and Methods
Animals
Normal adult male Sprague-Dawley rats were obtained from
Harlan (200–250 g, Indianapolis, IN). 6–8 weeks old male WT mice
(C57BL/10ScSnJ) and mice with a homozygous deletion of TLR4
(C57BL/10ScN) were obtained from Jackson Laboratory (Bar
Harbor, ME). Mice with a homozygous deletion for the TLR4 allele
are viable, fertile, normal in size and do not display any gross physical
abnormalities. The animals were fed a standard diet and acclimated
in a quiet quarantine room for 1 week before the experiments.
Figure 9. siRNA targeting of STAT3 changed the chemokine expression profile in TLR4KO MSC. TLR4KO MSC were plated in 12-well
plates at 0.5610
5cells?well
21?ml
2124 h prior to siRNA transfection. The lipofectamine-siRNA complex (100 nM) was then added on culture day 2.
Medium was then changed after 2 days (day 4 in culture) of transfection. 3 days after transfection (day 5 in culture), the supernatant was collected
from TLR4KO MSC either transfected with STAT3 siRNA or GAPDH siRNA and analyzed using a cytokine array assay. A: representative cytokine array
blots are shown. B: Array signals from images of scanned X-ray films were analyzed and qualified as pixel densities. Data are the combination of two
independent experiments. Results are mean 6 SEM, n=4/group, * p,0.05 vs. GAPDH-ablated TLR4KO group.
doi:10.1371/journal.pone.0014206.g009
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The animal protocol was reviewed and approved by the Indiana
Animal Care and Use Committee of the Indiana University
(Animal protocol 3583 and 3281). All animals received humane
care in compliance with the ‘‘Guide for the Care and Use of
Laboratory Animals’’ (NIH publication No. 85-23, revised 1996).
All Animals received humane care in compliance with the ‘‘Guide
for the Care and Use of Laboratory Animals’’ (NIH publication
No. 85-23, revised 1985). Isolated heart from adult rats and bone
marrow from adult mice were used for experiments. The Public
Health Service Animal Welfares Assurance and Animal Care
Forms describe the facilities in which they are maintained and
methods of care in compliance with NIH guidelines.
Preparation of MSC
A single-step stem cell purification method was employed as
previously described [26,57]. Briefly, MSC were collected from the
bilateral femurs and tibias of mice after sacrifice by removing the
epiphyses and flushing the shaft with complete media—Iscove’s
Modified Dulbecco’s Medium (IMDM; Invitrogen, Carlsbad, CA)
and 10% fetal bovine serum (Invitrogen)—using a syringe with a
26G needle. Cells were disaggregated by vigorous pipetting and
were passed through a 30-mm nylon mesh to remove any
remaining clumps of tissue. Cells were centrifuged for 5 min at
500 g at 24uC. The cell pellet was then re-suspended and cultured
in 75 cm
2 culture flasks in complete media at 37uC with 5% CO2.
MSC preferentially attached to the polystyrene surface and after
48 h, non-adherent cells in suspension were discarded. Fresh
complete media was added and replaced every three or four days
thereafter. When the cells reached 90% confluence, MSC cultures
were recovered by the addition of a solution 0.25% trypsin-EDTA
(Invitrogen) and passaged. Cell passage was restricted to passages
6–10 for the experiments. Cell counts were determined using an
automatic cell counter (Nexcelom cellometer
TM Auto T4,
Bioscience LLC, Lawrence, MA).
Flow cytometry analysis
The following primary antibodies were used: anti-Sca-1-PE,
anti-CD34-PE, anti-CD11b-APC, anti-CD45-FITC, anti-CD106-
FITC, anti-CD90-PE, anti-CD117-APC, anti-CD44-PE and the
recommended isotype control for each fluorochrome (BD
Biosciences, San Diego, CA). MSC were incubated with specific
primary antibodies for 1 h and analyzed by flow cytometry with a
FACSCalibur flow cytometer (BD Biosciences).
MSC differentiation
0.5610
5 MSC were seeded in a 2-well glass chamber at a
concentration of 0.1610
6/ml. After reaching confluence, MSC
were induced to differentiate by using a differentiation kit (R&D
Systems, Minneapolis, MN). Briefly, MSC were incubated with
adipogenic or osteogenic medium for 3-4 weeks with medium
replacement twice a week. After the designated incubation period,
cells were stained with anti-fatty-acid binding protein 4 (FABP4)
for the adipogenic group and anti-osteopontin for the osteogenic
group. MSC were then incubated with a Northern Lights 557
(NL557)-conjugated secondary antibody. Uninduced MSC were
used as negative controls and maintained in complete media. Cell
morphology and fluorescence were examined under an inverted
fluorescence microscope (Nikon TE2000U, Nikon, Melville, NY)
at 1006 magnification. Images were digitalized with QCapture
(QImaging, Surrey, BC) and transferred to Adobe Creative Suite 4
(Adobe Systems Inc., San Jose, CA).
5-Bromo-29-deoxy-uridine (BrdU) incorporation
BrdU incorporation was used to measure DNA synthesis in a
colorimetric immunoassay. Briefly, MSC were plated in 96-well
Corning plates (Corning, NY) at 5000 cells/well and allowed to
adhere overnight in complete media at 37uC with 5% CO2.
Subsequently, the cells were incubated with 10 mM BrdU for 24
hours. The labeled cells were then fixed with ethanol. Prior to
incubation with a monoclonal antibody to BrdU, DNA was
partially digested with nucleases to allow the antibody to access the
incorporated BrdU. The absorbance of the samples was
determined with a standard microplate (ELISA) reader at 405
nm with a reference wavelength at 490 nm.
VEGF, HGF and IGF-1 ELISA
0.5610
5 cells?well
21?ml
21 from each cell line were plated and
the supernatants collected after 24 h incubation and measured for
VEGF, HGF and IGF-1 production using a commercially
available ELISA kit (R&D). All samples and standards were
measured in duplicate. The absorbance of the samples was
determined with a standard microplate (ELISA) reader at 450 nm
with a reference wavelength at 540 nm.
Cytokine array assay
0.1610
6 cells?well
21?ml
21 from each cell line were plated and
the supernatants collected after 24 h incubation and measured for
cytokines, chemokines and TIMP metallopeptidase inhibitor 1
(TIMP1) production using a mouse cytokine array kit (R&D).
Briefly, the array membranes immobilized with capture antibodies
were blocked and then incubated with 1 ml of conditioned
medium for 2 h at room temperature. After washing out the
unbound proteins, the membranes were then incubated with a
biotin-conjugated detection antibody cocktail. Membranes were
then incubated with HRP-conjugated streptavidin for 30 min at
room temperature. The signals were detected by using Super-
Signal West Pico stable peroxide solution (Pierce, Rockford, IL).
Signal densities were compared using TotalLab software (Nonlin-
ear USA, Inc., Durham NC).
Protein Isolation and Western Blot Analysis
Western blot analysis was performed to measure the activation
of PI-3K, AKT, ERK, and STAT3. Cell extracts were prepared
by direct lysis of cells in cold RIPA buffer (Sigma, St Louis, MO)
containing a protease inhibitor cocktail and phosphatase inhibitor
cocktail 2 (Sigma). Lysates were then centrifuged at 12000 rpm for
10 minutes. Protein extracts (10 mg/lane) were electrophoresed on
a 4–12% Bis Tris gel (Invitrogen) and transferred to a
nitrocellulose membrane. The membranes were incubated in 5%
Figure 10. siRNA targeting of STAT3 abolished cardioprotection of TLR4KO MSC. One million TLR4KO MSC transfected with STAT3 siRNA
or GAPDH siRNA were infused into the coronary circulation prior to global ischemia. Intracoronary infusion of TLR4KO MSC transfected with GAPDH
siRNA provided greater cardioprotection compared to TLR4KO MSC transfected with STAT3 siRNA. The left ventricular function of hearts infused with
GAPDH ablated TLR4KO MSC (black, n=4) and STAT3 ablated TLR4KO MSC (hatched bars, n=4) is presented. A: representative trace recorded from
hearts infused with GAPDH or STAT3 ablated MSC. The line-graphs represent left ventricular function parameters over time including LVDP (% of
equilibrium, B), + dP/dt (% of equilibrium, D), 2 dP/dt (% of equilibrium, F) and EDP (H). Recovery at end reperfusion is indicated in bar graph form:
LVDP (C), + dP/dt (E), 2dP/dt (G) and EDP (I). All results are reported as the mean 6 SEM. * p,0.05 vs. GAPDH group.
doi:10.1371/journal.pone.0014206.g010
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phospho(P)-PI-3K, total(T)-PI-3K, P-AKT, T-AKT, P-ERK, T-
ERK, P-STAT3 and T-STAT3 (Cell Signaling Technology, Inc.
Boston, MA) followed by incubation with horseradish peroxidase-
conjugated goat anti-rabbit IgG secondary antibody and detection
using SuperSignal West Pico stable peroxide solution (Pierce,
Rockford, IL). Actin levels were measured to ensure equal loading
of protein. Band densities were compared using TotalLab software
(Nonlinear USA, Inc.).
Isolated heart preparation (Langendorff)
Rats were anesthetized (sodium pentobarbital, 60 mg/kg i.p.)
and heparinized (500 U i.p.), and hearts were rapidly excised via
median sternotomy and placed in a modified 4 uC Krebs–
Henseleit (KH) solution (119 mM NaCl, 20.8 mM NaHCO3,1 1
mM dextrose, 12 mM CaCl2 (2H2O), 47 mM KCl, 11.7 mM
MgSO4(7H2O), and 11.8 mM KH2PO4). The aorta was
cannulated and the heart was perfused under constant pressure
(mean 75 mmHg) with oxygenated (95% O2/5% CO2) Krebs–
Henseleit solution (37uC). A left atrial resection was performed to
allow the insertion of a water-filled latex balloon through the
atrium into the ventricle. The balloon was adjusted to a desired
mean end diastolic pressure (EDP) of 5–10 mmHg, and the hearts
were allowed to equilibrate for 15 minutes. Pacing wires were fixed
to the right atrium and the left ventricle, and the hearts were paced
at approximately 6 Hz, 3V, 2 ms (350 bpm) during equilibration
and reperfusion to ensure a standard heart rate between groups.
Immediately prior to global ischemia, the hearts were randomly
assigned to one of three treatment groups: 1) vehicle (1 ml of KH),
2) one million WT MSC or 3) one million TLR4KO MSC. The
treatements were administered by intracoronary infusion through
the aortic cannula over one minute. To create warm global
ischemia, the perfusion to the heart was stopped at the end of the
assigned treatment using a three-way stopcock above the aortic
root and the heart was placed in a 37uC degassed organ bath.
After 25 min of warm ischemia, the hearts were reperfused for 40
minutes. The left ventricular developed pressure (LVDP), end
diastolic pressure (EDP), maximum +dP/dt (rate of pressure rise
during ventricular contraction) and –dP/dt (rate of pressure fall
during ventricular relaxation) were continuously recorded using a
PowerLab 8 preamplifier/digitizer (AD Instruments Inc., Milford,
MA) and a Mini Mac computer (Apple Computer Inc., Cupertino,
CA).
siRNA transfection
siRNA that specifically targeted mouse STAT3 were designed
according to the software provided by Dharmacon siDESIGN
center (Dharmacon Research, Lafayette, CO). SiRNA sequences
(CAGCACAACCUUCGAAGAA) corresponding to residues
517–535 of the coding region of mouse STAT3 were selected.
MSC from the same starting cell isolation were transfected with
the aforementioned specific STAT3 siRNA at a concentration of
100 nM. MSC transfected with siRNA targeting GAPDH were
used as control (Silencer GAPDH siRNA, Ambion, TX).
Transfection was performed with Lipofectamine 2000 (Invitrogen,
CA) per the manufacturers’ instructions. Briefly, 24 h prior to
siRNA transfection, cells were plated in 12-well plates at
0.5610
5cells?well
21?ml
21. On culture day 2, cells were washed
with Optimem media (Invitrogen) and the lipofectamine-siRNA
complex (100 nM) was then added. After 1 day of transfection (day
3 in culture), the lipofectamine-siRNA complex was washed out
and the IMDM medium containing 10% FBS and 1% antibiotics
was added to the cells and allowed to incubate for an additional 2
days. Medium was then changed after 2 days (day 4 in culture) of
transfection. 3 days after transfection (day 5 in culture), the
supernatant was collected for VEGF, HGF and IGF-1 ELISA as
well as cytokine array analysis. Cell extracts were prepared for
performing Western blots. For the isolated heart preparation, 3
days after transfection, MSCs were trypsinized, collected and
counted with the aid of the automated cell counter (Nexcelom
Bioscience). One million viable cells were isolated. The cells were
centrifuged at 300 g, the media was removed, and the cells were
resuspended in 1 ml of KH solution (37uC). Over the course of 1
min immediately prior to ischemia, the MSC solution was infused
into the coronary circulation.
Reagents
All standard chemicals were obtained from Sigma.
Data analysis
All reported values are mean 6 SEM. LVDP, +/2dp/dt are
presented as a percentage of the baseline. Statistical differences
between the control groups and those obtained under various
treatment conditions were determined using a 1-way ANOVA
followed by a Holm-Sidak post hoc analysis. Values of p,0.05
were judged to be statistically significant.
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